BioWorld Asia

Feb. 10, 2010

First Deal for Apeiron a Doozy: Getting up to $329M from GSK

Apeiron Biologics AG licensed its lead program APN01, a recombinant form of human angiotensin converting enzyme 2 (ACE2), to London-based GlaxoSmithKline plc in a deal valued at up to €236 million (US$329.4 million). (BioWorld International) Read More

Cancer Research Charity Signs AstraZeneca Discovery Pact

Vaccine for Maternal Malaria May be Possible as Soon as 10 Years

NewCo News: Sistemic Raises $1M to Fund New Drug Discovery Platform

NeuroSearch Rockets on Good Phase III Data for Huntington's

Isotechnika 'Lux' Out; Partner Files First Voclosporin NDA

Bankers Predict 25% Growth for U.S. IPO Market This Year

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...